title: [Preparation and in vitro targeting of follicle stimulating hormone polypeptide modified nanoparticles].
abstract: OBJECTIVE
  To prepare follicle stimulating hormone (FSH) polypeptide modified nanoparticles (NP) in order to achieve specific ovarian tumor targeting.
  
  
  METHODS
  Expression of FSH receptor protein in human liver cancer and ovarian cancer cell lines BEL-7402, SKOV-3 and Caov-3 was detected by immunocytochemistry. The polypeptide fragment of FSH beta 81-95 amino acids (FSHL81-95) was synthesized and covalently coupled to NP. The specific binding of FSHL81-95 and FSHL81-95-NP was examined by fluorescence microscopy and flow cytometry.
  
  
  RESULTS
  BEL-7402 and SKOV-3 cells were negative for FSH receptor staining, while Caov-3 cells were positive. The diameters of NP were about 100 nm, with a Zeta potential of -25 mV or so. Caov-3 cells showed a more specific interaction with FSHL81-95-NP than SKOV-3 cells (4.17 +/- 0.86 and 2.30 +/- 0.21; P < 0.05). The uptake of FSHL81-95-NP was more than NP in Caov-3 cells (4.17 +/- 0.86 and 0.41 +/- 0.32; P < 0.05). FSHL81-95-NP showed a selective targeting at Caov-3 cells compared with control NP.
  
  
  CONCLUSIONS
  FSH polypeptide modified NP could selectively target ovarian cancer cells expressing FSH receptor, which might contribute to specific endocytosis mediated by FSH receptor.
authors.affiliation: Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Zhang
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Gao
authors.forename: Hong
authors.initials: H
authors.lastname: Sun
authors.forename: Cong-jian
authors.initials: CJ
authors.lastname: Xu
mesh_terms: D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage / Q000494:pharmacology; D037201:Follicle Stimulating Hormone, beta Subunit / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology; D053758:Nanoparticles; D010051:Ovarian Neoplasms / Q000473:pathology*; D010316:Particle Size; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D011962:Receptors, FSH / Q000378:metabolism*
chemical_list: D043373:Follicle Stimulating Hormone, Human; D037201:Follicle Stimulating Hormone, beta Subunit; D010455:Peptides; D011962:Receptors, FSH